Thymosin Alpha-1
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Thymosin Alpha-1 is listed as immune / thymic peptide.
- •Immunomodulation
- •Chronic hepatitis B/C
- •Sepsis adjunct
- •Cancer adjunct
Regulatory status: Approved in 35+ countries; FDA Orphan Drug.
Structure & Properties
Compound: Thymosin Alpha-1; also known as Tα1, Thymalfasin, Zadaxin.
Pharmacologic class: Immune / Thymic Peptide.
Known delivery routes: Subcutaneous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Thymic peptide — activates dendritic and NK cells; increases Th1 cytokines (IFN-γ, IL-2); reduces viral load; reduces sepsis mortality in some trials.
- •Immune restoration in immunocompromised states
- •Adjunct viral hepatitis therapy
- •Possible mortality benefit in severe sepsis
Human Research
Evidence grade: Clinical RCT (Limited)
Clinical RCT (Limited). Phase II/III; FDA NDA rejected; approved CN/IT/SE Asia.
Laboratory Research
Phase II/III; FDA NDA rejected; approved CN/IT/SE Asia
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Typically 2× weekly SubQ. Consistent day-of-week schedule.
Potential interactions and combinations to avoid
- •Active immunosuppression (transplant) — pro-immune activity
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Injection site reactions
- •Fever
- •Autoimmune flare (theoretical)
Contraindications
- •Immunosuppression for transplant
- •Pregnancy
- •Hypersensitivity
- •Autoimmune disease in active flare (immune activation may worsen symptoms)
- •Solid-organ or stem-cell transplant recipients on immunosuppression (rejection risk)
- •Concurrent biologic immunosuppressants or systemic corticosteroids without specialist input
- •Untreated acute infection requiring standard antimicrobial therapy
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 1.6 mg 2×/week
Frequency: Twice weekly
Cycling: Continuous in chronic infection; pulsed in immune support protocols.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •LL-37 or KPV for antimicrobial / mucosal protocols
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
Any consistent time — typically morning, 2–3× weekly.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Continuous in chronic infection; pulsed in immune support protocols.
Timing & Interactions
- ·Active immunosuppression (transplant) — pro-immune activity
- ·LL-37 or KPV for antimicrobial / mucosal protocols
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Thymosin Alpha-1 and sync them to Vial Lab.
Benefits
- ·Immune restoration in immunocompromised states
- ·Adjunct viral hepatitis therapy
- ·Possible mortality benefit in severe sepsis
Risks
- ·Injection site reactions
- ·Fever
- ·Autoimmune flare (theoretical)
Contraindications
- ·Immunosuppression for transplant
- ·Pregnancy
- ·Hypersensitivity
- ·Autoimmune disease in active flare (immune activation may worsen symptoms)
- ·Solid-organ or stem-cell transplant recipients on immunosuppression (rejection risk)
- ·Concurrent biologic immunosuppressants or systemic corticosteroids without specialist input
- ·Untreated acute infection requiring standard antimicrobial therapy
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Approved in 35+ countries; FDA Orphan Drug
Veterinary Use (Pets)
Immune modulation in chronic viral or immunodeficient animals.
Functional Groups
Cited Works
Tap any study to open the published work.